Dr. Philippe Ruszniewski on NETTER-1 Study Results

Philippe Ruszniewski, MD
Published: Saturday, Sep 26, 2015



Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.

The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR). 

There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.

<<< View more from the 2015 European Cancer Congress



Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.

The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR). 

There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.

<<< View more from the 2015 European Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x